Monica Lopez, MD
Obstetrics & Gynecology · Fort Worth, TXNPI 1508081316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $680 and has fallen 97.5% since, to $17 in 2025.
Across 139 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$532
- Pfizer$343
- Astellas Pharma US Inc$240
- Exeltis, USA Inc.$194
- Hologic Sales And Service, LLC$147
- Lupin Inc.$147
- plus $1K from 25 others
Across 5 payments — averaging $1,627,124 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$8.1M
What the payments were for
- Food & beverage$2,65499%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $532 |
| Pfizer | 23 | $343 |
| Astellas Pharma US Inc | 13 | $240 |
| Exeltis, USA Inc. | 11 | $194 |
| Hologic Sales And Service, LLC | 5 | $147 |
| Lupin Inc. | 7 | $147 |
| Mayne Pharma Commercial LLC | 5 | $127 |
| Sumitomo Pharma America, Inc. | 5 | $117 |
| Organon | 5 | $92 |
| Intuitive Surgical | 1 | $79 |
| Merck | 4 | $65 |
| Shield Therapeutics Inc | 1 | $64 |
| Therapeuticsmd, Inc. | 3 | $57 |
| Duchesnay USA Incorporated | 3 | $53 |
| Pacira Pharmaceuticals Incorporated | 2 | $51 |
| Coopersurgical, Inc. | 2 | $37 |
| Avion Pharmaceuticals | 2 | $36 |
| Innovation Technologies Inc | 1 | $33 |
| Vertex | 1 | $31 |
| Johnson & Johnson | 2 | $31 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Evofem Biosciences, Inc. | 1 | $24 |
| Millicent US Inc | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Meditrina | 1 | $18 |
| Aspira Women's Health Inc | 1 | $18 |
| Minerva Surgical, Inc | 1 | $17 |
| Myovant Sciences Inc. | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Biogen | 1 | $13 |
How this compares
$2,680 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 18 | $850 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Fort Worth
- David MorelandFort Worth$63K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Dale StovallDallas$590K
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
- Lisa JukesBee Cave$270K
- Susan CrockettLive Oak$269K
- Henry Garza IiiSan Antonio$258K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.